Remission of screen-detected metabolic syndrome and its determinants: an observational study by Corine den Engelsen et al.
den Engelsen et al. BMC Public Health 2012, 12:778
http://www.biomedcentral.com/1471-2458/12/778RESEARCH ARTICLE Open AccessRemission of screen-detected metabolic
syndrome and its determinants: an observational
study
Corine den Engelsen1*, Kees J Gorter1, Philippe L Salomé2, Maureen van den Donk1 and Guy E Rutten1Abstract
Background: Early detection and treatment of the metabolic syndrome may prevent diabetes and cardiovascular
disease. Our aim was to assess remission of the metabolic syndrome and its determinants after a population based
screening without predefined intervention in the Netherlands.
Methods: In 2006 we detected 406 metabolic syndrome cases (The National Cholesterol Education Program’s Adult
Treatment Panel III (NCEP ATP III) definition) among apparently healthy individuals with an increased waist
circumference. They received usual care in a primary care setting. After three years metabolic syndrome status was
re-measured. We evaluated which baseline determinants were independently associated with remission.
Results: The remission rate among the 194 participants was 53%. Baseline determinants independently associated
with a remission were the presence of more than three metabolic syndrome components (OR 0.46) and higher
levels of waist circumference (OR 0.91), blood pressure (OR 0.98) and fasting glucose (OR 0.60).
Conclusions: In a population with screen-detected metabolic syndrome receiving usual care, more than half of the
participants achieved a remission after three years. This positive result after a relatively simple strategy provides a
solid basis for a nation-wide implementation. Not so much socio-demographic variables but a higher number and
level of the metabolic syndrome components were predictors of a lower chance of remission. In such cases,
primary care physicians should be extra alert.
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The term ‘Metabolic Syndrome’ (MetS) refers to a clus-
tering of cardiovascular risk factors, which is clinically
relevant to identify people with a high cardiovascular
risk. People with MetS have an increased risk of devel-
oping both type 2 diabetes and cardiovascular disease
[1-4] and an up to fourfold increased risk of mortality
from cardiovascular disease [2,3]. Early detection and
adequate treatment can modify or even abolish the risk
factors and thus prevent cardiovascular disease [5-8].
Identifying people who are less likely to achieve a remis-
sion is important, in order to give them more attention* Correspondence: c.denengelsen-2@umcutrecht.nl
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distribution, and reproduction in any mediumand to intensify their treatment. Several studies assessed
remission of the MetS, all following a structured inter-
vention. Such interventions are usually not in accordance
with daily practice. Especially interventions performed in
a randomized controlled trial setting often provide data
in a clinical context that does not exist outside the trial
itself, thereby limiting generalizability [9]. The more a
follow-up trajectory fits in daily practice, the better a
screening strategy can be implemented. However, data
on remission of the MetS following usual care are
scarce. The same applies to prognostic determinants
for remission.
Our aim was to assess the remission of the MetS in
individuals with screen-detected MetS and to determine
which determinants at the time of diagnosis predict re-
mission three years after screening, followed by usual
care in a primary care setting.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Study design and population
Between October 2006 and April 2007 the ‘IJsselstein
Screening for Central Obesity to detect metabolic
syndrome’ was conducted in the city of IJsselstein
among 12.000 individuals. The aim was to determine
the feasibility and yield of a screening for MetS with
self-measurement of waist circumference as the first
step [10]. A total of 1.721 individuals with a self-
measured increased waist circumference (≥ 88 cm in
women, ≥ 102 cm in men) underwent all study proce-
dures. They were aged 20–70 years and not previously
diagnosed with diabetes, hypertension, dyslipidemia or
cardiovascular disease. 473 of them were detected with
MetS. Participants were advised to contact their primary
care center for the results of the screening; no other
intervention was performed. In case of detected cardio-
vascular risk factors, they should receive usual care
according to the guidelines ‘Cardiovascular risk manage-
ment’ [11] and ‘Type 2 Diabetes Mellitus’ [12] of the
Dutch College of General Practitioners. Follow-up mea-
surements took place three years after screening, in
November and December 2009. 406 of the 473 partici-
pants with screen-detected MetS were invited for
follow-up measurements. The other 67 were no longer
eligible because of illness and death or because they
were no longer visiting the same primary care phys-
ician. Three and six weeks after the invitation, remin-
ders were sent to the non-responders.
The study was approved by the medical ethics com-
mittee of the University Medical Center Utrecht, the
Netherlands. Written informed consent was obtained
from all participants.
Measurements
Both at screening and three years later at follow-up the
same measurements were performed. In a physical
examination body weight, height, waist circumference
and blood pressure were measured. Venous blood sam-
ples were drawn after an overnight fast to determine
fasting blood glucose, triglycerides and high-density lipo-
protein (HDL) cholesterol. A detailed description of
these measurements was described previously [10].
At baseline participants had completed a questionnaire
to determine ethnicity, education level and lifestyle fac-
tors (smoking habits, physical activity). Education level
was dichotomized, in which ‘high’ was defined as having
completed a level of secondary education which permits
entry to college. Smoking was regarded positive when
the participant was currently smoking; in case of former
or never smoking it was regarded negative. Physical
activity was assessed using the validated SQUASH
questionnaire [13], which measures habitual activities
with respect to occupation, leisure time, household,transportation means, and other daily activities. The
results were dichotomized based on the Dutch Stand-
ard Healthy Movement: a minimum of thirty minutes
of moderately intensive exercise at least five days a
week [14].
At follow-up, smoking status and level of physical ac-
tivity were re-evaluated using the same questionnaire, in
which participants were also questioned about consult-
ing a dietician. Data about prescribed cardiovascular
medication at the time of follow-up were collected from
the physician’s electronic medical record. As a measure
of follow-up behavior we used the number of visits to
the practice nurse during the first year following screen-
ing, collected from the electronic medical record.
Outcome measure
The MetS was defined according to The National
Cholesterol Education Program’s Adult Treatment
Panel III (NCEP ATP III) criteria, namely the presence
of at least three of the following five components:
increased waist circumference (≥ 88 cm in women,
≥ 102 cm in men), elevated blood pressure (systolic
≥ 130 and/or diastolic ≥ 85 mmHg), elevated triglycerides
(≥ 1.7 mmol/L), elevated fasting glucose (≥ 6.1 mmol/L),
and reduced HDL cholesterol (< 1.0 mmol/L in men,
< 1.3 mmol/L in women) [15]. We defined remission as
having less than three MetS components at follow-up,
thereby no longer fulfilling the criteria for the presence
of the MetS. We did not take the use of cardiovascular
medication into account in the definition of remission.
Determinants
Both socio-demographic and clinical characteristics were
considered as potential baseline determinants of remis-
sion. We considered several determinants with regard to
the follow-up period as potential confounders (consult-
ation behavior, weight loss, change in level of physical
activity and prescription of cardiovascular medication
for a specific MetS component).
Data analysis
Categorical variables are reported as numbers and per-
centages, continuous variables as means with standard
deviations (SD) and non-normally distributed variables
as median with interquartile range.
We checked for selection bias by testing for differences
in baseline variables (gender, age, body mass index
(BMI), waist circumference, HDL cholesterol, fasting glu-
cose, triglycerides and blood pressure) between respon-
ders and non-responders, and between participants
(responders willing to participate) and non-participants
(responders who indicated not to be interested in follow-
up measurements). Chi-square tests were used for cat-
egorical variables, independent samples t-tests for
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Whitney tests for non-normally distributed continuous
variables. The same tests were used to test for baseline
differences between participants who achieved a remis-
sion and those who did not. Paired samples t-tests for
normally distributed variables and the Wilcoxon signed-
rank test for non-normally distributed variables were
used to test for a significant change in mean risk factor
levels between screening and follow-up. A p-value < 0.05
was considered significant.
For logistic regression analyses, triglyceride level was
log transformed because of its skewed distribution.
Waist circumference and HDL cholesterol were also
transformed, taking into account the gender specific
thresholds. The gender specific threshold was extracted
from the values obtained in the examinations. The new
variables indicate the absolute difference with the gender
specific threshold.
Univariable and multivariable logistic regression ana-
lyses were performed to assess determinants of remis-
sion. All variables considered as potential baseline
determinants (Table 3) were entered into model 1, ex-
cept for BMI, because of the high correlation with waist
circumference. In model 2 the follow-up determinants
were included as co-variables. The models were reduced
by means of backward selection, based on the p-value of
the Wald test. The variables with the highest p-value
were one by one removed, until the p-value for each
variable became < 0.20. All MetS components as wellTable 1 Baseline characteristics of the population with screen
measurements, divided into those who did and did not achie
Baseline characteristics Total g
n= 19
Gender (% male) 104 (53
Age (years) 49.0 ± 1
Ethnicity (% Western European) 187 (96
Higher educated (%) 68 (35.
Smoking (%) 43 (22.
Physical activity (% adhering to Dutch
Standard Healthy Movementa)
102 (53
BMI (kg/m2) 30.1 ± 3
Waist circumference (cm) ♂ 109.9 ±
♀ 99.5 ± 8
Blood pressure (mmHg) Systolic 143.5 ±
Diastolic 88.0 ± 7
Triglycerides (mmol/L) 1.9 (1.6
HDL cholesterol (mmol/L) ♂ 1.1 ± 0.
♀ 1.3 ± 0.
Fasting glucose (mmol/L) 5.3 ± 1.
Data are reported as means ± standard deviation or number (percentage). Non-norm
a a minimum of thirty minutes of moderately intensive exercise at least five days aas gender were kept in the model, regardless of their
p-value. Analyses were performed using Statistical
Package of Social Sciences (SPSS, version 17.0).
Results
The response rate was 86 %. 194 responders were willing
to participate in follow-up examinations. The study flow
chart is shown in Figure 1. 53.6 % of the participants
were male and the mean age was 49.0 years (SD 10.1).
Baseline characteristics are shown in Table 1.
Comparing the participants with the combined group
of non-participants and non-responders showed that
participants were older (49 versus 46 years, p < 0.01)
and more often visited the practice nurse at least twice
in the year following screening (69 versus 56 %,
p < 0.01). Non-responders were significantly younger
than responders (40 versus 49 years, p < 0.001) and more
often of non-Western European origin (15 versus 4 %,
p < 0.01) whereas responders more often than non-
responders achieved the Dutch Standard Healthy Move-
ment (42 versus 58 %, p = 0.03) and more often visited
the practice nurse at least twice (65 versus 47 %,
p = 0.01). Participants more often had a higher education
level (35 versus 27 %, p < 0.05) than non-participants.
However, they less often achieved the Dutch Standard
Healthy Movement at baseline compared to non-
participants (53 versus 64 %, p = 0.03).
Three years after screening a significant improvement
in almost all MetS components was observed. However,-detected metabolic syndrome participating in follow-up
ve a remission
roup Remission P-value
4 Yes n =103 No n=91
.9) 53 (51.5) 51 (56.0) 0.52
0.1 48.2 ± 10.9 49.8 ± 9.0 0.27
.4) 100 (97.1) 87 (95.6) 0.58
1) 37 (35.9) 31 (34.1) 0.79
2) 22 (21.4) 21 (23.1) 0.77
.4) 52 (51.5) 49 (53.8) 0.74
.7 29.7 ± 3.5 30.7 ± 3.8 <0.05
7.4 106.6 ± 5.5 113.3 ± 7.6 < 0.001
.8 98.4 ± 8.9 101.0 ± 8.7 0.18
14.9 142.0 ± 12.5 145.3 ± 17.2 0.14
.5 87.1 ± 7.3 89.1 ± 7.6 0.07
-2.3) 1.9 (1.6-2.3) 1.9 (1.7-2.5) 0.24
3 1.1 ± 0.3 1.1 ± 0.2 0.44
3 1.4 ± 0.3 1.3 ± 0.3 0.04
1 5.0 ± 0.6 5.5 ± 1.5 0.01




Invited for follow-up measurements
n = 406
Not eligible for follow-up measurements
(moved, deceased, critical illness, other reasons)
n = 67
Non-responders
n = 55 (14%)
Responders
















Figure 1 Study flowchart. Legend: * Reasons for exclusion: pregnancy (n = 1), illness (n = 1), stay abroad (n = 1).
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and without a remission of the MetS (Table 2). Of the
194 participants diagnosed with MetS, 103 (53.1 %) no
longer fulfilled the MetS criteria according to their
follow-up levels of the components. The participants
who still fulfilled the MetS criteria at follow-up had a
higher BMI and fasting glucose at baseline. Men not
achieving a remission had a higher waist circumference,
whereas women not achieving a remission had a signifi-
cantly lower HDL cholesterol level at baseline (Table 1).
At follow-up, 57 (29.4 %) participants received antihy-
pertensive medication, 55 (28.4 %) received a statin and
eight (4.1 %) were on blood glucose lowering medica-
tion. Fibrates or nicotinic acid were not prescribed. In
132 (68.0 %) participants, no medication for a specific
MetS component was prescribed.
The presence of more than three MetS components
and a higher waist circumference and fasting glucose
were the baseline determinants significantly associated
with a lower chance of remission in univariable regres-
sion analysis (Table 3).The odds ratios for the variables that were independ-
ently associated with remission (p < 0.20) are shown in
Table 4. When evaluating only baseline determinants,
age, a higher waist circumference and glucose, a lower
HDL cholesterol and the presence of more than three
MetS components were independently associated with a
lower chance of remission. When adding follow-up
determinants as co-variables, age and HDL cholesterol
no longer showed an independent association with re-
mission, whereas weight loss during follow-up did. Each
kilogram of weight loss increased the likelihood of
achieving a remission 1.2 times.
Discussion
We performed a screening in primary care among ap-
parently healthy individuals, to detect new MetS cases.
Participants were only advised to contact their primary
care center for the results of the screening. Upon
contacting they were expected to receive usual care
according to existing guidelines; no specific interven-
tion was designed. More than half of the participants
Table 2 Mean risk factor levels and mean change from baseline
n=194 2006 2009 Mean change from baseline (95 % C.I.)
Weight (kg) 93.1 ± 15.2 90.6 ± 16.1 −2.5 ± 6.4 (−3.4 ; -1.6)
BMI (kg/m2) 30.1 ± 3.7 29.2 ± 4.1 −0.9 ± 2.0 (−1.2 ; -0.6)
Waist circumference (cm) ♂ 109.9 ± 7.4 106.2 ± 9.4 −3.6 ± 6.4 (−4.9 ; -2.4)
♀ 99.5 ± 8.8 95.9 ± 10.7 −3.6 ± 6.9 (−5.1 ; -2.1)
Blood pressure (mmHg) Systolic 143.5 ± 14.9 135.4 ± 13.6 −8.1 ± 12.1 (−9.8 ; -6.4)
Diastolic 88.0 ± 7.5 82.4 ± 7.7 −5.6 ± 7.7 (−6.7 ; -4.5)
Triglycerides (mmol/L) 1.9 (1.6-2.3) 1.8 (1.3-2.3) −0.3 ± 1.1 (−0.4 ; -0.1)
HDL cholesterol (mmol/L) ♂ 1.1 ± 0.3 1.2 ± 0.3 0.1 ± 0.1 (0.03 ; 0.08)
♀ 1.3 ± 0.3 1.4 ± 0.3 0.2 ± 0.2 (0.05 ; 0.14)
Fasting glucose (mmol/L) 5.3 ± 1.1 5.4 ± 0.7 0.2 ± 0.9 (0.0 ; 0.3)
Data are reported as means ± standard deviation or percentage. Non-normally distributed variables are reported as median (25th - 75th percentile).
Table 3 Associations of potential determinants with remission in univariable logistic regression analysis
n (%) Remission
rate (%)
ORa (95 % C.I.) P-value
Baseline determinants
Age (years) 0.98 (0.95 ; 1.01) 0.27
Gender ♂ 104 (53.6) 51.0 Ref.
♀ 90 (46.4) 55.6 1.20 (0.68 ; 2.12) 0.52
Ethnicity Western European 187 (96.4) 53.5 Ref.
Other 7 (3.6) 42.9 0.65 (0.14 ; 3.00) 0.58
Higher educated No 126 (64.9) 52.4 Ref.
Yes 68 (35.1) 54.4 1.09 (0.60 ; 1.96) 0.79
Smoking No 151 (77.8) 53.6 Ref.
Yes 43 (22.2) 51.2 0.91 (0.46 ; 1.78) 0.77
Number of metabolic syndrome components 3 149 (76.8) 59.7 Ref.
≥ 4 45 (23.2) 31.1 0.30 (0.15 ; 0.62) <0.01
BMI (kg/m2) 0.92 (0.85 ; 1.00) 0.05
HDL cholesterol (mmol/L) 2.64 (0.97 ; 7.18) 0.06
Waist circumference (cm) 0.93 (0.89 ; 0.97) <0.001
Blood pressure (mmHg) Systolic 0.99 (0.97 ; 1.01) 0.14
Diastolic 0.96 (0.93 ; 1.00) 0.07
Triglycerides (mmol/L) 0.57 (0.29 ; 1.11) 0.10
Fasting glucose (mmol/L) 0.55 (0.36 ; 0.85) <0.01
Follow-up determinants
≥ 2 consultations with practice nurse No 60 (30.9) 51.7 Ref.
Yes 134 (69.1) 53.7 1.09 (0.59 ; 2.00) 0.07
Cardiovascular medication, specific for
metabolic syndrome component
No 132 (68.0) 56.1 Ref.
Yes 62 (32.0) 46.8 0.69 (0.38 ; 1.26) 0.23
Consultation with dietician No 133 (68.6) 55.6 Ref.
Yes 61 (31.4) 47.5 0.72 (0.39 ; 1.33) 0.30
Change in physical activity level (hours/week) 1.00 (0.98 ; 1.01) 0.48
Weight loss (kg) 1.14 (1.07 ; 1.20) <0.001
a Odds ratio per one-unit change.
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Table 4 Determinants independently associated (p <0.20) with remission in multivariable logistic regression analysis
Model 1 Model 2
ORa (95 % C.I.) ORb (95 % C.I.) P-value ORa (95 % C.I.) ORb (95 % C.I.) P-value
Age (years) 0.98 (0.94 ; 1.01) 0.18
Gender (female) 1.37 (0.69 ; 2.73) 0.37 1.23 (0.58 ; 2.61) 0.59
Waist circumference (cm) 0.93 (0.89 ; 0.97) 0.56 (0.39 ; 0.81) <0.01 0.91 (0.87 ; 0.96) 0.46 (0.30 ; 0.71) <0.01
HDL cholesterol (mmol/L) 2.52 (0.73 ; 8.69) 1.31 (0.91 ; 1.90) 0.14 1.69 (0.48 ; 5.89) 1.17 (0.81 ; 1.69) 0.41
Fasting glucose (mmol/L) 0.68 (0.43 ; 1.10) 0.65 (0.38 ; 1.11) 0.11 0.60 (0.36 ; 1.00) 0.56 (0.31 ; 1.00) 0.05
Triglycerides (mmol/L) 0.94 (0.41 ; 2.16) 0.97 (0.68 ; 1.40) 0.88 0.64 (0.27 ; 1.55) 0.82 (0.56 ; 1.21) 0.32
Systolic blood pressure (mmHg) 0.99 (0.97 ; 1.01) 0.84 (0.60 ; 1.18) 0.32 0.98 (0.95 ; 1.00) 0.70 (0.49 ; 1.01) 0.05
≥ 4 metabolic syndrome components 0.48 (0.20 ; 1.13) 0.09 0.46 (0.18 ; 1.19) 0.11
Weight loss (kg) 1.18 (1.10 ; 1.27) <0.001
Model 1: only baseline determinants were entered into the model. The metabolic syndrome components and gender were kept in the model, regardless of their
p-value.
Model 2: both baseline and follow-up determinants were entered into the model. The metabolic syndrome components and gender were kept in the model,
regardless of their p-value.
a Odds ratio per one-unit change.
b Odds ratio per standard deviation increase.
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the metabolic syndrome criteria three years later. The
presence of more than three MetS components and a
higher waist circumference, glucose level and systolic
blood pressure were independently associated with a
lower chance of remission.
Several studies have assessed the remission of MetS,
all after an intervention. These interventions include
diet (remission rate 21-61 %) [16-18], exercise programs
(remission rate 42-58 %) [19,20], combinations of both
(remission rate 67 %) [21], bariatric surgery (remission
rate up to 95 %) [22-24] and medication such as metfor-
min, fenofibrate and orlistat (remission rate 23-44 %)
[25,26]. However, data about remission of the MetS with-
out predefined intervention unless the advice to contact
the primary care center are scarce. Two randomized con-
trolled trials reported remission rates for their control
groups of 9 and 18 % [26,27]. Our higher remission rate
might be explained by the intensity of our usual care,
which was presumably higher than control group care as
described by Orchard et al. and Bo et al. In these studies
participants received lifestyle recommendations once,
while the majority of our participants was seen several
times by the practice nurse. The remission rate of 52 %
observed in a prospective study more closely resembled
our remission rate, which could be explained by an inter-
vention more in agreement with our usual care [28].
However the follow-up period was only six months; it is
uncertain what would have happened after this relatively
short intervention period.
In our study, not only individuals with diabetes or car-
diovascular disease were excluded. Individuals were only
eligible for screening if they were not previously diagnosed
with hypertension or dyslipidemia and did not useantihypertensive, blood glucose lowering or cholesterol
lowering medication: they were apparently healthy. The
shock of suddenly being diagnosed with several risk fac-
tors might have been an extra impulse to change lifestyle,
which might have contributed to the high remission rate.
Two studies compared baseline characteristics between
participants who did and did not achieve a remission
[17,19]. As in our study, the participants who did not
achieve a remission had worse baseline values than the
participants who did achieve a remission. This might be
explained by the fact that achieving a remission is more
difficult for participants with higher risk factor levels.
Baseline HDL cholesterol level was not associated with re-
mission, in contrast to baseline levels of glucose, waist cir-
cumference and systolic blood pressure, where lower
baseline levels were associated with a higher chance of re-
mission. HDL dysfunction could be an underlying reason
for the absence of an association between baseline HDL
cholesterol level and remission. Dysfunctional HDL parti-
cles lose their anti-inflammatory and atheroprotective
properties. This condition is closely linked to obesity and
to inflammation and might be more prevalent among
people with high HDL concentrations. In Western popu-
lations, individuals with glucose intolerance or those at
risk for cardiometabolic disease – people with MetS –
could be affected by impaired function of HDL [29,30].
Study limitations and strengths
This is the first study assessing remission of MetS after
screening among apparently healthy people, without a
predefined intervention program. The follow-up period
of three years provides us with intermediate-term
results. A shorter follow-up period might give too opti-
mistic remission rates, because treatment effects and
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economic and demographic, biochemical and clinical
variables were taken into account, as well as lifestyle fac-
tors. Our data on the prescription of cardiovascular
medication were based on prescription according to the
electronic medical record of the primary care physician.
Actual use of the prescribed medication might be lower,
since medication compliance, especially in primary pre-
vention, is not optimal [31-33].
According to the NCEP ATP III criteria, when a pa-
tient is on drug treatment for a specific MetS compo-
nent (antihypertensive drug treatment, blood glucose
lowering treatment or treatment with a fibrate or nicoti-
nic acid for a reduced HDL cholesterol or an increased
triglyceride level) this component should be regarded as
present, irrespective of the actual level of the component
[15]. This means that for example the blood pressure
component will be regarded as positive as long as some-
one is on antihypertensive drug treatment, despite per-
fect blood pressure levels and thereby a reduced
cardiovascular risk. Therefore, to gain insight into the
actual reduction in cardiovascular risk achieved by re-
mission, we chose not to take drug treatment for a spe-
cific MetS component into our definition of remission.
In fact, the definition of the MetS provides a good
screening tool to detect people with a high cardiovascu-
lar risk, but the current NCEP ATP III definition is less
suitable for evaluating the effect of an intervention on
changes in risk. If we had taken prescription of medica-
tion for a specific MetS component into account in our
definition our remission rate would have been 49.0 %.
The overall response rate was good, although a substan-
tial amount of the responders indicated not to be inter-
ested in participating in follow-up. This resulted in a
relatively small study population. One might assume that
people willing to participate were the more motivated
patients, leading to potential bias for the generalization of
the results. Indeed the participants more often entered a
follow-up regimen after screening than the non-
participants and non-responders. Whether their higher
motivation also has led to a higher remission rate is ques-
tionable. However, we have to take into account this po-
tential bias in interpreting the results. Especially younger
people were less interested in follow-up measurements. At
the initial screening, it were also the younger subgroups in
which an invitation reminder was necessary to get a suffi-
cient response. Apparently first it takes more effort to in-
volve younger people in screening, and then we gain less
insight into the impact of the screening for their cardio-
vascular health. It would be interesting to know the remis-
sion rate among the younger non-participants, since half
of the people detected with the MetS were younger than
50 years [10]. Age, however, was not significantly asso-
ciated with achieving a remission in multivariable analysis.Conclusions
Screening with self-measurement of waist circumference
as a first step detected 473 MetS cases among apparently
healthy people. Among those who were willing to partici-
pate in follow-up examinations, 53 % no longer had the
MetS after three years. This positive result after a rela-
tively simple strategy provides a solid basis for a nation-
wide implementation. However, people < 50 years seem
less willing to participate in screening and follow-up, a
finding that should be taken into account for future
screening strategies. Not so much socio-demographic
variables but a higher level of the MetS components and
the presence of more than three components were base-
line predictors of a lower chance of remission. In such
cases, primary care physicians should be extra alert.
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